News ArchivesRead News
New research program tackles Parkinson’s disease
Tuesday December 19, 2006
December 14, 2006(University of Wisconsin System) - A new research collaboration at the University of Wisconsin-Madison aims to move promising new therapies for Parkinsons disease from primates to patients.
Based at the Wisconsin National Primate Research Center and named the Preclinical Parkinsons Disease Research Program, the collaboration became official in November. Joseph Kemnitz, professor of physiology and Primate Center director, is the programs executive director. Renowned Parkinsons disease expert Marina Emborg, senior scientist at the Primate Center and in the department of anatomy, is scientific director. "Our goal is to hasten discoveries that will lead to new therapies for Parkinsons disease, with an emphasis on cell and gene-based therapies," says Kemnitz.
Through the new program, the Primate Center is poised to become the countrys centralized resource for Parkinsons disease research using nonhuman primate models, especially macaques, Kemnitz says. Program collaborators and funding agencies that will help develop the necessary laboratory and animal resources at the Primate Center include WinCon, a biotechnology company in Nanning, Guangxi, China; researchers at the Beijing Institute of Geriatrics, and an anonymous foundation.
"Macaques are regarded by many as the most useful model for Parkinsons research," Kemnitz says. "These collaborators chose the Wisconsin National Primate Research Center because we have a well established infrastructure for conducting research using nonhuman primates, and UW-Madison has a broad range of expertise directly relevant to this program."
That expertise lies in the UW-Madisons renowned capabilities in brain imaging technology, stem cell biology and clinical biomanufacturing. Researchers from the Primate Center, Waisman Center, School of Medicine and Public Health, School of Pharmacy, and other campus entities are already developing promising Parkinsons therapies based on embryonic stem cell derivations, trophic (nutritive) factors, compounds called thiazolidenediones, deep brain stimulation and other treatment avenues.
"Were committed to finding a cure for Parkinsons disease," Emborg says.
Recent NewsMay 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia
May 5 - Parkinson's in a dish: Researchers reproduce brain oscillations
May 5 - ‘Hunger Hormone’ Could Help Treat Parkinson’s Disease
May 3 - Antibiotic doxycycline may offer hope for treatment of Parkinson's disease
May 1 - Impulse Control Disorders in Parkinson's Disease: Building Physician, Patient Awareness
Apr 28 - Does Parkinson’s disease begin in the gut?
Apr 28 - New empathy-creating digital device could be revolutionary for caregivers
Apr 24 - Treating Depression With Deep Brain Stimulation Works—Most of the Time
Apr 24 - Parkinson’s disease shows links to depression
Apr 21 - TOLEDO Trial: Apomorphine Infusions Reduce 'Off' Time in Parkinson's Disease
Apr 21 - New drug provides long-awaited breakthrough for Parkinson's psychosis
Apr 12 - Obstructive Sleep Apnea Affects Cognition in Parkinson's Disease
Apr 11 - Seattle boxing gym giving hope to Parkinson's patients
Apr 10 - A new rhythm
Apr 10 - Brain cells reprogrammed to make dopamine, with goal of Parkinson's therapy
Apr 6 - FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Apr 5 - Combatting the isolation of young onset Parkinson's disease
Apr 1 - The Kid is Alright